1. Home
  2. PBH vs CELC Comparison

PBH vs CELC Comparison

Compare PBH & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prestige Consumer Healthcare Inc.

PBH

Prestige Consumer Healthcare Inc.

HOLD

Current Price

$55.21

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$125.97

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBH
CELC
Founded
1996
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.1B
IPO Year
2004
2017

Fundamental Metrics

Financial Performance
Metric
PBH
CELC
Price
$55.21
$125.97
Analyst Decision
Buy
Strong Buy
Analyst Count
3
9
Target Price
$75.33
$112.56
AVG Volume (30 Days)
490.0K
665.8K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
2.88
N/A
EPS
2.78
N/A
Revenue
$975,777,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.31
$720.19
P/E Ratio
$20.27
N/A
Revenue Growth
36.77
N/A
52 Week Low
$51.24
$9.64
52 Week High
$88.00
$129.09

Technical Indicators

Market Signals
Indicator
PBH
CELC
Relative Strength Index (RSI) 38.51 57.27
Support Level $51.24 $100.58
Resistance Level $63.56 N/A
Average True Range (ATR) 1.84 7.28
MACD 0.09 -0.10
Stochastic Oscillator 12.34 86.78

Price Performance

Historical Comparison
PBH
CELC

About PBH Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: